Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091735 | 0.80 | SLC6A3 (0.40) | SMN1; SMN2GAAMAPTMEN1KMT2A | |
| SCHEMBL2627851 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2DDB1CRBNMAPTMEN1 | |
| SCHEMBL8993494 | 0.76 | ALDH1A1 (0.38) | SMN1; SMN2DDB1CRBNMAPTMEN1 | |
| SCHEMBL157619 | 0.76 | BRD4 (0.50) | SMN1; SMN2DDB1CRBNPRCPGAA | |
| SCHEMBL9295153 | 0.76 | BRD4 (0.50) | SMN1; SMN2DDB1CRBNPRCPGAA | |
| SCHEMBL6247618 | 0.76 | BRD4 (0.50) | SMN1; SMN2DDB1CRBNPRCPGAA | |
| Hydrochloric Acid SCHEMBL8743281 | 0.73 | PRCP (0.40) | SMN1; SMN2PRCPGAAMAPTMEN1 | |
| SCHEMBL1498959 | 0.72 | DDB1 (0.44) | SMN1; SMN2DDB1CRBNPRCPMAPT | |
| SCHEMBL1499114 | 0.72 | DDB1 (0.44) | SMN1; SMN2DDB1CRBNPRCPMAPT | |
| SCHEMBL6268350 | 0.71 | PRCP (0.46) | SMN1; SMN2DDB1CRBNPRCPGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0461783-B1 | Photographic developer composition | KNAPP AUDENRIED W (US) | 1996-12-04 | — | — | EP | claimed |
| EP-0508691-B1 | Gluconic-acid based developer composition | KNAPP AUDENRIED W (US) | 1994-01-12 | — | — | EP | claimed |
| EP-0508691-A1 | Gluconic-acid based developer composition | Knapp, Audenried W. (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0461783-A1 | Photographic developer composition | Knapp, Audenried W. (US) | 1991-12-18 | — | — | EP | claimed |
| EP-0170861-B1 | 3-AMINOCARBONYLMETHOXY-5-PHENYLPYRAZOLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Kali-Chemie Pharma GmbH (DE) | 1988-03-09 | — | — | EP | claimed |
| US-4617258-A | WATER SOLUBLE GROUP 8 COMPOUNDS | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1986-10-14 | — | — | US | claimed |
| EP-0091788-A2 | Silver halide photographic material | KONICA CORPORATION (JP) | 1983-10-19 | — | — | EP | claimed |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| CN-107108492-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2021-03-19 | — | — | CN | disclosed |
| CN-112370452-A | Heterocyclic amides as kinase inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-0091788-A2 | Silver halide photographic material | KONICA CORPORATION (JP) | 1983-10-19 | — | — | EP | disclosed |
| EP-0089101-A2 | Direct positive image-forming process | KONICA CORPORATION (JP) | 1983-09-21 | — | — | EP | disclosed |
| US-4083722-A | BROMINE-FREE, A 3-PYRAZOLIDONE COMPOUND, A HYDROXYBENZENE COMPOUND, AN ALKALINE PRESERVATIVE AND AN ACCELERATOR | ANNEMAN WILLIAM ALEXANDER | 1978-04-11 | — | — | US | disclosed |
| US-3993770-A | Penicillins | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-23 | — | — | US | disclosed |
| US-3993642-A | Penicillins | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-23 | — | — | US | disclosed |
| US-3974288-A | ANTIBACTERIAL ACTIVITY | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
| US-3970458-A | PHOTOGRAPHY | EASTMAN KODAK COMPANY (US) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478438-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | SMN1; SMN2 1593/4885DDB1 931/4885CRBN 3903/4885 |
| US-20210253532-A1 | Heterocyclic Amides as Kinase Inhibitors | MAP3K19, MAP3K20, MAP3K1 | SMN1; SMN2 4513/4885DDB1 2273/4885CRBN 2028/4885 |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | SMN1; SMN2 4513/4885DDB1 2273/4885CRBN 2028/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | SMN1; SMN2 4513/4885DDB1 2273/4885CRBN 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.